Spots Global Cancer Trial Database for Relmacabtagene Autoleucel in Patients With LBCL
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Relmacabtagene Autoleucel in Patients With LBCL
Official Title: A Real World Study of Treatment of Relmacabtagene Autoleucel in Relapsed or Refractory Large B-Cell Lymphoma
Study ID: NCT06142175
Conditions
Interventions
Study Description
Brief Summary: To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world
Detailed Description: This is a post-marketing, multicenter, observational real-world study, including prospective and retrospective studies. The purpose of this study is to collect efficacy and safety data over a 6-month period following treatment of adult patients with r/r LBCL with Relmacabtagene autoleucel. The treating physicians in the study will determine the most appropriate diagnostic and therapeutic regimen for their patients based on clinical practice.There will be no therapeutic intervention as a result of this study. There will be no subgroups of any kind in this study, and subgroup analyses will be performed based on the actual data collected during the analysis.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,, Shanghai, Shanghai, China
Contact Details
Name: Weili Zhao, PhD
Affiliation: Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Role: PRINCIPAL_INVESTIGATOR
Name: Huiqiang Huang, PhD
Affiliation: Sun Yat-sen University
Role: PRINCIPAL_INVESTIGATOR
Name: Liang Huang, PhD
Affiliation: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Role: PRINCIPAL_INVESTIGATOR
Name: Ping Li
Affiliation: Shanghai Tongji Hospital, Tongji University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Heng Mei
Affiliation: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Role: PRINCIPAL_INVESTIGATOR
Name: Hongmei Jing
Affiliation: Peking University Third Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Wenbin Qian
Affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University
Role: PRINCIPAL_INVESTIGATOR
Name: Depei Wu
Affiliation: The First Affiliated Hospital of Soochow University
Role: PRINCIPAL_INVESTIGATOR
Name: Ying Lu
Affiliation: Ningbo University People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Huilai Zhang
Affiliation: Tianjin Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Qingyuan Zhang
Affiliation: Harbin Medical University Tumor Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Dehui Zou
Affiliation: Hematology Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Yao Liu
Affiliation: Chongqing University Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Jianqiu Wu
Affiliation: Jiangsu Provincial Tumor Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Yajun Li
Affiliation: Hunan Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Ru Feng
Affiliation: Southern Medical University, China
Role: PRINCIPAL_INVESTIGATOR
Name: Yuhua Li
Affiliation: Nanfang Hospital, Southern Medical University
Role: PRINCIPAL_INVESTIGATOR
Name: Zhifeng Li
Affiliation: The First Hospital of Xiamen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
